All results

12 results for risk and resilience during covid 19

• ACTIV-4d or Novel Experimental COVID Therapies Affecting Host Response (NECTAR)

  The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients…

  Ages

  18 Years - N/A

  Sexes

  All

• Kinect-HD2

  This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to…

  Ages

  18 Years - 75 Years

  Sexes

  All

• RESOLVE - Lung

  This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE). This is a randomized, double-blind, placebo-controlled study…

  Ages

  18 Years - N/A

  Sexes

  All

• JNT-517

  The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD)…

  Ages

  18 Years - 65 Years

  Sexes

  All

• SMART

  The purpose of this trial is to generate clinical evidence on valve safety and performance of self-expanding (SE) versus balloon-expandable (BE) transcatheter…

  Ages

  18 Years - N/A

  Sexes

  All

• TN-31 JAKPOT T1D

  A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and…

  Ages

  12 Years - 35 Years

  Sexes

  All

• TAK-999-3003

  The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-alpha-1 antitrypsin…

  Ages

  18 Years - N/A

  Sexes

  All

• ARGX-113-2007

  This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy…

  Ages

  18 Years - N/A

  Sexes

  All

• Fasting ENHANCE

  Grounded in the principles of geroscience, the proposed Fasting ENHANCE study will test whether a time restricted eating (TRE) regimen can improve cognitive…

  Ages

  65 Years - N/A

  Sexes

  All

• Tazemetostat in patients with recurrent/refractory and/or metastatic MPNST

  This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant…

  Ages

  12 Years - 99 Years

  Sexes

  All